Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin Infusions in Severe POTS
NCT03365414Phase 3Withdrawn
- Sponsor
- University of Alberta
- Start
- Jan 2022
- Primary completion
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of albumin (human) in postural orthostatic tachycardia syndrome (POTS), sponsored by University of Alberta. Planned start Jan 2022; status: withdrawn.
02
Drugs
albumin (human)
03
Conditions
postural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT03365414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03365414.